Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
Dynavax Adjuvanted Clover Bio’s COVID-19 Vaccine Booster Shows Durable Protection Against Omicron
Clover Biopharmaceuticals Ltd’s follow-up analysis for efficacy in the SPECTRA Phase 2/3 trial of SCB-2019 COVID-19 vaccine provided high and…
The Daily Biotech Pulse: AbbVie’s Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Recap: Dynavax Technologies Q4 Earnings
Dynavax Technologies (NASDAQ:DVAX) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Dynavax Technologies Q4 EPS $0.80 Beats $0.69 Estimate, Sales $195.07M Miss $208.87M Estimate
Dynavax Technologies (NASDAQ:DVAX) reported quarterly earnings of $0.80 per share which beat the analyst consensus estimate of $0.69 by 15.94 percent. This is a 671.43 percent increase over losses of $(0.14) per share
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell
• Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter.
A Preview Of Dynavax Technologies’s Earnings
Dynavax Technologies (NASDAQ:DVAX) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement.
Analysts estimate that Dynavax Technologies will report an earnings per share (EPS) of $0.69.
A Preview Of Dynavax Technologies’s Earnings
Dynavax Technologies (NASDAQ:DVAX) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement.
Analysts estimate that Dynavax Technologies will report an earnings per share (EPS) of $0.69.
Valneva Confirmed Clinical Trial and Regulatory Submission Timelines for its Inactivated COVID-19 Vaccine Candidate VLA2001
Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today confirms the previously communicated timelines of its clinical trials and regulatory submissions for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
10 Biggest Price Target Changes For Wednesday
Tigress Financial lifted the price target on McDonald's Corporation (NYSE: MCD) from $271 to $314. McDonald's shares fell 0.1% to close at $267.88 on Tuesday.